Journal: bioRxiv

Article Title: Butyrate regulates the blood-brain barrier transport and intra-endothelial accumulation of Alzheimer’s disease Amyloid-beta peptides

doi: 10.1101/2025.10.24.684335

Figure Lengend Snippet: Cells were incubated for 6 h under the following conditions: control (no treatment), butyrate alone (10 nM), butyrate + inhibitor, or inhibitor alone. In the last 30 minutes of each treatment, all groups received F-Aβ42 (1 μM) and insulin (50 nM). A & B. Butyrate reduced F-Aβ42 accumulation compared to control. Butyrate co-incubation with 0.5 µM trametinib (MEK inhibitor) increased F-Aβ42 accumulation compared to the butyrate alone group, as shown in the histogram of intracellular MFI (A) and bar chart (B) showing fold change of median fluorescence ± standard deviation. C & D. In another experiment, butyrate decreased F-Aβ42 accumulation compared to control, and co-incubation with 10 nM VX-745 (p38 inhibitor) did not alter F-Aβ42 accumulation, as shown in the histogram of intracellular fluorescence (C) and bar chart (D) representing fold change of median fluorescence ± standard deviation. One-way ANOVA followed by Bonferroni post-test; *p-value<0.05, **p-value<0.01.

Article Snippet: A separate experiment was conducted for each of these kinase phosphorylation inhibitors: 10 μM MK2206 (AKT), 100 nM Rapamycin (mTOR), 0.5 μM trametinib (MEK), 10 nM VX-745 (p38), obtained from Selleckchem, TX.

Techniques: Incubation, Control, Fluorescence, Standard Deviation

Journal: The EMBO Journal

Article Title: Immediate early splicing controls translation in activated T-cells and is mediated by hnRNPC2 phosphorylation

doi: 10.1038/s44318-025-00374-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: VX-745 (p38 inhibitor) , Biomol , Cay18075-1.

Techniques: Recombinant, Construct, Sequencing, Reverse Transcription, SYBR Green Assay, Marker, Western Blot, Software, Electroporation, Blocking Assay, Imaging, Mass Spectrometry